Nonalcoholic steatohepatitis (NASH) is defined as the presence of hepatic steatosis and inflammation with hepatocyte injury (ballooning) with or without fibrosis. NASH is often a “silent” liver disease. Estimated prevalence of NASH ranges from 3% to 5% in different studies. The prevalence of NASH-related cirrhosis in the general population is not known. Herein, we report a case of a young female presented with NASH-related cirrhosis in the setting of poorly controlled celiac disease (CD) and microscopic colitis. A variety of liver abnormalities have been observed in patients with CD, but this unique constellation of the gut and liver pathologies has not been reported previously.
1. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
2. LaBrecque D, Abbas Z, Anania F, Ferenci F, Khan AG, Goh K-L, et al. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, World Gastroenterology Organization Global Guidelines, June 2012. Available from: http://www.worldgastroenterology.org/assets/export/userfiles/2012_NASHandNAFLD_Final_long.pdf. [Last accessed on 2012 August 01].
3. Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011;128:2436-43.
4. Canbay A, Gieseler RK, Gores GJ, Gerken G. The relationship between apoptosis and non-alcoholic fatty liver disease: An evolutionary cornerstone turned pathogenic. Z Gastroenterol 2005;43:211-7.
5. Eade MN, Cooke WT, Williams JA. Liver disease in Crohn’s disease. A study of 100 consecutive patients. Scand J Gastroenterol 1971;6:199-204.
6. Vajro P, Fontanella A, Mayer M, De Vincenzo A, Terracciano LM, D’Armiento M, et al. Elevated serum aminotransferase activity as an early manifestation of gluten-sensitive enteropathy. J Pediatr 1993;122:416-9.
7. Kaukinen K, Halme L, Collin P, Färkkilä M, Mäki M, Vehmanen P, et al. Celiac disease in patients with severe liver disease: Gluten-free diet may reverse hepatic failure. Gastroenterology 2002;122:881-8.
8. Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol 2004;2:107-12.
9. Volta U. Liver dysfunction in celiac disease. Minerva Med 2008;99:619-29.
10. Volta U. Pathogenesis and clinical significance of liver injury in celiac disease. Clin Rev Allergy Immunol 2009;36:62-70.
11. Bardella MT, Fraquelli M, Quatrini M, Molteni N, Bianchi P, Conte D. Prevalence of hypertransaminasemia in adult celiac patients and effect of gluten-free diet. Hepatology 1995;22:833-6.
12. Bardella MT, Vecchi M, Conte D, Del Ninno E, Fraquelli M, Pacchetti S, et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. Hepatology 1999;29:654-7.
13. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23.
14. Rafiq N, Younossi ZM. Effects of weight loss on nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:427-33.
15. Rahimi AR, Daryani NE, Ghofrani H, Taher M, Pashaei MR, Abdollahzade S, et al. The prevalence of celiac disease among patients with non-alcoholic fatty liver disease in Iran. Turk J Gastroenterol 2011;22:300-4.
16. Stewart M, Andrews CN, Urbanski S, Beck PL, Storr M. The association of coeliac disease and microscopic colitis: A large population-based study. Aliment Pharmacol Ther 2011;33:1340-9.